Biogen BIIB
NASDAQ BIIB
$220.73 +5.23 (+2.43%)
As of: Sep 21, 2026 · 11:44 AM EDT

Biogen (BIIB) Total Debt Growth (5y) (2014 - 2026)

Analysis

Biogen (BIIB) Total Debt Growth (5y) (2014 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn
10 Insmed 26.19 Bn 25.03 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.16%
Mar 31, 2026 -2.85%
Dec 31, 2025 -3.28%
Sep 30, 2025 -3.28%
Jun 30, 2025 -2.82%
Mar 31, 2025 1.52%
Dec 31, 2024 1.55%
Sep 30, 2024 1.54%
Jun 30, 2024 1.13%
Mar 31, 2024 2.70%
Dec 31, 2023 3.61%
Sep 30, 2023 4.20%
Jun 30, 2023 1.17%
Mar 31, 2023 1.15%
Dec 31, 2022 1.13%
Sep 30, 2022 -0.72%
Jun 30, 2022 4.91%
Mar 31, 2022 4.90%
Dec 31, 2021 4.88%
Sep 30, 2021 4.82%